Arrowhead Pharmaceuticals Inc ARWR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARWR is a good fit for your portfolio.
News
-
Turnstone Biologics Appoints William Waddill to its Board of Directors
-
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
-
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
-
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
Trading Information
- Previous Close Price
- $22.61
- Day Range
- $21.75–22.76
- 52-Week Range
- $20.67–42.48
- Bid/Ask
- $22.33 / $23.00
- Market Cap
- $2.77 Bil
- Volume/Avg
- 965,833 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 13.32
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 525
- Website
- https://www.arrowheadpharma.com
Comparables
Valuation
|
Metric
|
ARWR
|
AVIR
|
ALNY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 15.15 | 0.56 | — |
Price/Sales | 13.32 | — | 9.92 |
Price/Cash Flow | — | — | 194.13 |
Price/Earnings
ARWR
AVIR
ALNY
Financial Strength
|
Metric
|
ARWR
|
AVIR
|
ALNY
|
|---|---|---|---|
Quick Ratio | 3.46 | 17.86 | 2.86 |
Current Ratio | 3.73 | 18.24 | 3.08 |
Interest Coverage | −14.29 | — | −3.36 |
Quick Ratio
ARWR
AVIR
ALNY
Profitability
|
Metric
|
ARWR
|
AVIR
|
ALNY
|
|---|---|---|---|
Return on Assets (Normalized) | −28.28% | −15.46% | −5.60% |
Return on Equity (Normalized) | −69.29% | −16.16% | — |
Return on Invested Capital (Normalized) | −50.13% | −19.92% | −16.93% |
Return on Assets
ARWR
AVIR
ALNY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gbxbwssgh | Fxsy | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vvyqnpjv | Hntrvk | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Npmvjgch | Cvqzl | $98.1 Bil | |
MRNA
| Moderna Inc | Vpyztyff | Ngm | $39.1 Bil | |
ARGX
| argenx SE ADR | Jvphtxrf | Mtgv | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Mmghyhh | Rvqk | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pdcnxphr | Lsfgfxn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Klswfpdx | Thqczy | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bncknjplv | Bpyxn | $12.5 Bil | |
INCY
| Incyte Corp | Cttztjlf | Xndhrd | $11.9 Bil |